It is known to play a role in cancer drug resistance by modulating several targets and in the activation of AMPK.27, 28, 29 SIRT1 mainly regulates various transcription factors such as tumour suppressor p53, forkhead box protein O1 (FOXO1) and forkhead box class O 3a (FOXO3a) of forkhead transcription factors, peroxisome proliferator‐activated receptor‐γ coactivator (PGC)‐1α, histone acetyltransferase p300 and nuclear factor kappa B (NFkB) in the nucleus.29, 30 Thus, inhibition of SIRT1 expression could have promising therapeutic potential for NSCLC. This evidence concerns the gene FOXO1 and non-small cell lung carcinoma.